Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Toric IOLs
Infection
Dry eye
 
 
Survey

Do you repeat SLT treatment more than twice in the same section of TM?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


April 16, 2014
High astigmatism
High-cylinder toric IOL better for high astigmatism
Cataract patients who have astigmatism of greater than 2.5 D are likely to benefit more from the implantation of a high-cylinder toric IOL than from the implantation of a low-cylinder toric IOL combined with LRI, according to recent research. More...
Endophthalmitis research
Endophthalmitis most often caused by Staphylococcus
Endophthalmitis is most often caused by coagulase-negative Staphylococcus, and the antibiotics vancomycin and ceftazidime seem to perform well in treating it. That was one of the findings of a recently published 25-year retrospective study. More...
Treatment of dry eye
Phase 1 study of dry eye solution launched
Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome. More...
Product Profile
ZEISS Cataract Suite markerless
Align toric IOLs and skip the manual marking and data transfer steps with products designed to work together for markerless toric IOL alignment.
Read more
Event Profile
120th Congress of the French Society of Ophthalmology
Dates: 10–13 May 2014
Venue: Palais des Congrès, Porte Maillot, Paris
The SFO’s annual congress will bring together more than 8000 attendees, 100 exhibitors, 60 scientific sessions, 300 oral communications, 60 workshops, symposia with foreign Societies, 450 e-posters and e-films … Hot Topics will be discussed, a live surgery session on Monday 12th will be programmed, and a specific space (2nd floor) will be dedicated to technology and communication.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: